NÖK Therapeutics, Inc. is a clinical-stage biotechnology innovator redefining the next generation of cancer immunotherapy by harnessing the innate power of natural killer (NK) cells. The company is focused on developing autologous, non-engineered NK cell therapies that restore the body’s first line of immune defense without the need for lymphodepletion, a major barrier in current cell therapy paradigms.